secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvex, Inc. (MOVE)
CIK:        0001734750
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001213900-22-048144
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Movano Q2 net loss $6.9M; advances Ring beta tests, hypoxia study meets FDA SpO2 accuracy
--------------------------------------------------------------------------------

- Net loss $6.9M ($0.21/sh) vs $4.7M ($0.15/sh) in Q2 2021; no revenue as development-stage company.
- Cash $21.3M at June 30, 2022, down from $33.6M at Dec 31, 2021.
- Plans DTC launch of Movano Ring in H1 2023; beta partners include Stanford, major pharma, diabetes device firm.
- Hypoxia study with UCSF: Ring achieved 2% SpO2 error margin (FDA requires 4%); larger pivotal study planned.
- Two new patents granted for SoC; planning BP and glucose clinical studies in Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1734750/000121390022048144/0001213900-22-048144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1734750/000121390022048144/ea164341-8k_movanoinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-048144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer